发明名称 |
Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
摘要 |
Soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in chick and mouse and thereby inhibits human tumor growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble non glycosylated CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumors using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues are presented. |
申请公布号 |
US8192744(B2) |
申请公布日期 |
2012.06.05 |
申请号 |
US20100660886 |
申请日期 |
2010.03.05 |
申请人 |
STROMBLAD STAFFAN;PALL TAAVI;KOGERMAN PRIIT;IBCC HOLDING AS |
发明人 |
STROMBLAD STAFFAN;PALL TAAVI;KOGERMAN PRIIT |
分类号 |
A61K38/16;A61K39/00 |
主分类号 |
A61K38/16 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|